http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113368111-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-498 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-498 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 |
| filingDate | 2020-03-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-04-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-04-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-113368111-B |
| titleOfInvention | Anti-tumor effect of phenazine carboxylic acid compounds |
| abstract | The invention belongs to the technical field of antitumor medicine, and particularly relates to an application of an antitumor compound shown as a formula I, namely dibenzo [ a, c ]]Application of phenazine-11-carboxylic acid in antitumor drugs. The MTT method is adopted to test the inhibition effect of the compound on human colorectal cancer cells HCT-115 and human breast cancer cells MCF-7. Experiments prove that the compound of the invention has obvious proliferation inhibition effect on the two tumor cells, thereby providing a new choice for treating related tumors. The compound has simple structure and good activity, can be used as a leading compound of an anti-cancer medicament, and has good application prospect. Formula I |
| priorityDate | 2020-03-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 19.